Stock report · Delisted · Nasdaq
Verve Therapeutics Inc (VERV)
11.13USD Delisted Final close · Jul 24, 2025
VERV no longer trades. Verve Therapeutics was delisted from the Nasdaq in July 2025.
All prices on this page are historical. The last trade was on July 24, 2025, at $11.13.
VERV stock price history
Final trading statistics
- Final close
- $11.13
- Final trading day
- Jul 24, 2025
- Market cap at delisting
- $994.04M
- Shares outstanding
- 89.31M
- Final 52-week range
- $2.86 – $11.40
- Avg. volume (final 3 mo.)
- 4,948,589
- All-time high
- $73.99 · Sep 2021
- All-time low
- $2.97 · Apr 2025
- Return since IPO
- -65.1%
- Beta
- 2.24
- Book value / share
- $5.33
- Price / book
- 2.09
About Verve Therapeutics Inc
Verve Therapeutics, Inc. was a clinical-stage company in the United States developing gene editing medicines for cardiovascular disease. VERVE-101 was in the Heart-1 Phase 1b trial in people with heterozygous familial hypercholesterolemia (HeFH), with changes in blood PCSK9 and LDL-C tracked. VERVE-102 was in the Heart-2 Phase 1b trial in adults with HeFH and/or premature coronary artery disease.
VERVE-201 aimed to permanently switch off the ANGPTL3 gene in the liver, and VERVE-301 used in vivo gene editing to switch off the liver's LPA gene and lower blood Lp(a). The company had agreements with Beam Therapeutics Inc., Acuitas Therapeutics, Inc., Novartis Pharma AG for lipid technology, Eli Lilly and Company, and a Cas9 license from The Broad Institute and Harvard.
Known as Endcadia, Inc. until January 2019, it was incorporated in 2018 and based in Boston. It became a subsidiary of Ridgeway Acquisition Corporation as of July 25, 2025. Its stock was delisted from the Nasdaq in July 2025, with the last trade on July 24, 2025 at $11.13.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA
- Employees
- 274
- IPO date
- June 17, 2021
- Delisted
- July 24, 2025
- SEC CIK
- 1840574
Verve Therapeutics financials before the delisting
The last 5 fiscal years Verve Therapeutics reported as a public company, fiscal year ending December.
VERV revenue and net income
VERV earnings per share
VERV annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $32.33M | −$198.7M | −$2.35 |
| FY2023 | $11.76M | −$200.1M | −$3.12 |
| FY2022 | $1.94M | −$157.4M | −$2.92 |
| FY2021 | $0.00 | −$118.6M | −$8.40 |
| FY2020 | $0.00 | −$45.5M | −$4.99 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Verve Therapeutics stock FAQ
What happened to Verve Therapeutics stock?
Verve Therapeutics was delisted from the Nasdaq in July 2025. The final close was $11.13 on July 24, 2025.
Can I still buy VERV stock?
No. VERV is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on July 24, 2025.
What was the last price of VERV?
VERV last closed at $11.13 on July 24, 2025, which valued the company at about $994.04M.
How did Verve Therapeutics do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Verve Therapeutics reported revenue of $32.33M and net income of −$198.7M.
When did Verve Therapeutics go public?
Verve Therapeutics shares started trading on June 17, 2021.
VERV no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.